Patents Assigned to Proventiv Therapeutics, LLC
-
Patent number: 8592401Abstract: Methods and compositions comprising 1,25-dihydroxyvitamin D2 are disclosed. A method for lowering or maintaining lowered serum parathyroid hormone in human patients including administering to said patients an effective amount of 1,25-dihydroxyvitamin D2 to lower or maintain lowered serum parathyroid hormone levels is disclosed. Dosage forms and dosing regimens are also disclosed.Type: GrantFiled: April 25, 2008Date of Patent: November 26, 2013Assignees: Proventiv Therapeutics, LLC, Cytochroma Inc.Inventors: P. Martin Petkovich, Charles W. Bishop, Eric J. Messner, Keith H. Crawford
-
Publication number: 20130178451Abstract: The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.Type: ApplicationFiled: November 19, 2012Publication date: July 11, 2013Applicants: PROVENTIV THERAPEUTICS, LLC, CYTOCHROMA INC.Inventors: CYTOCHROMA INC., PROVENTIV THERAPEUTICS, LLC
-
Publication number: 20130131022Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.Type: ApplicationFiled: January 22, 2013Publication date: May 23, 2013Applicants: PROVENTIV THERAPEUTICS, LLC, CYTOCHROMA INC.Inventors: CYTOCHROMA INC., PROVENTIV THERAPEUTICS, LLC
-
Patent number: 8426391Abstract: Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.Type: GrantFiled: February 2, 2007Date of Patent: April 23, 2013Assignee: Proventiv Therapeutics, LLCInventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner
-
Patent number: 8361488Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.Type: GrantFiled: April 25, 2008Date of Patent: January 29, 2013Assignees: Cytochroma Inc., Proventiv Therapeutics, LLCInventors: Charles W. Bishop, Samir P. Tabash, Sammy Asiamah Agudoawu, Jay A. White, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich
-
Patent number: 8329677Abstract: The a method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.Type: GrantFiled: June 21, 2007Date of Patent: December 11, 2012Assignees: Cytochroma, Inc., Proventiv Therapeutics, LLCInventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner, Martin P. Petkovich, Christian F. Helvig
-
Patent number: 8207149Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.Type: GrantFiled: September 26, 2011Date of Patent: June 26, 2012Assignees: Cytochroma, Inc., Proventiv Therapeutics, LLCInventors: Samir P. Tabash, Jay A. White, Charles W. Bishop, Sammy A. Agudoawu, Eric J. Messner, P. Martin Petkovich
-
Publication number: 20090209501Abstract: The a method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.Type: ApplicationFiled: June 21, 2007Publication date: August 20, 2009Applicants: Proventiv Therapeutics, LLC., Cyctochroma, Inc.Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messener, Martin P. Petkovich, Christian F. Helvig
-
Publication number: 20090176748Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.Type: ApplicationFiled: April 25, 2008Publication date: July 9, 2009Applicants: CYTOCHROMA INC., PROVENTIV THERAPEUTICS, LLCInventors: Samir P. Tabash, Jay A. White, Charles W. Bishop, Sammy Asiamah Agudoawu